Despite the many challenges of 2020, Real Chemistry says revenue rose by a dizzying 67%, reaching $334 million in the U.S. It acquired seven companies and added 500 new employees to its payroll.
All of these changes, the agency says, place it in a better position to improve health outcomes. With offices across the U.S. and Europe, Real Chemistry believes the way to transformative change is through its uncommon combination of talents, disciplines and technologies.
In a year of so many changes, the company focuses on the three pillars it feels matter most. Job No. 1 has been responding to the pandemic, and it went all in to help employees, clients, healthcare workers and patients. It supported more than 50 pandemic-related initiatives, assisting clients in developing vaccines, therapeutics, diagnostics and devices. One example: In a partnership with California Life Sciences Association, it formed the COR dashboard, which tracks real-time media conversations around COVID-19.
Next, it focused on racial injustice, acting with urgency to close its diversity gap and embed diversity, equity and inclusion into every fiber of the organization. It is sharpening proprietary social listening, analytics and engagement tools, and new offers include Advanced Dashboards, which bring automation and efficiencies to marketing, communications and sales processes.
New accounts include Adaptive Biotechnologies, Ardelyx, Dova Pharmaceuticals and Vercyte.
And finally, thought leadership is focusing on burning healthcare topics, writing provocative POVs on healthcare best practices, innovation and the latest digital marketing and communications trends.
